Under the terms of the non-binding ‘letter of intent’, both companies are expected to conduct their due diligence review within the next 60-90 days.
The PocketECG, manufactured by Medicalgorithmics, Poland, has recently received CE mark approval for marketing throughout Europe.
The PocketECG’s automated analysis is said to allow physicians to monitor large numbers of patients simultaneously and saves time by eliminating the need to analyze electrocardiogram tracings once the device reports that an abnormal event has taken place.
Marek Dziubinski, co-founder and chief technology officer of Medicalgorithmics, said: “Similar in size to an MP3 player, patients find the PocketECG easy to use 24-hours-per-day in the comfort of their homes and when going about their normal activities.”